TAT-11: Improved Tumor Control and Absence of Late Neurotoxicity using Alpha (Bi213) as Compared to Beta(Y90) Labelled-DOTA-Substance P for the Treatment of Low-Grade Gliomas

Ottawa, ON, Canada (UroToday.com) Dr. Merlot described a comparative study of beta emitter Y90-DOTA-Substance P versus alpha emitter Bi213 conjugated to the same ligand in eight patients with low-grade gliomas. The study spanned a total of 18 years. In the Bi213 patients, no recurrence or late-time toxicity was observed while all of the Y90 some form of both after 18 years. There is a clear preference for alpha treatment. A dosage of 1.9 GBq of Bi213 should be sufficient. The dose limitation factor is edema.

Presented by: Proessor Adrian Merlo, University of Basel

Written by: William Carithers, Lawrence Berkeley National Laboratory at the 11th International Symposium on Targeted Alpha Therapy (TAT-10) April 1 - April 4, 2019 - Ottawa, ON, Canada

Login